Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2016

01-08-2016 | Original Article

Evaluation of bone mineral density in patients with hemoglobin H disease

Authors: Tahereh Zarei, Sezaneh Haghpanah, Shirin Parand, Hossein Moravej, Mohammad Hossein Dabbaghmanesh, Gholamhossein Ranjbar Omrani, Mehran Karimi

Published in: Annals of Hematology | Issue 8/2016

Login to get access

Abstract

Objectives

This study was conducted to assess bone mineral density (BMD) and bone mineral content (BMC) of patients with hemoglobin H (HbH) disease.

Methods

BMD and BMC were measured by dual energy X-ray absorptiometry of the lumbar spines and femur neck in 21 patients with Hb H disease over the age of 10 years.
An association of BMD with sex, age, hemoglobin, calcium, phosphorus, and serum ferritin level was also evaluated.

Results

Prevalence of BMD below the expected range for age in the lumbar spine and femur neck region in patients with HbH disease were 33.3 and 14.3 %, respectively. Lumbar BMD was significantly lower in the patients compared to healthy individuals (median (min-max) 0.725 (0.595–0.924) vs. 1.061 (0.645–1.238), P < 0.001)). There was no significant relationship between BMD in the lumbar and femur neck with any of the evaluated variables (P value >0.05).

Conclusion

Data regarding bone density in HbH disease is limited; osteoporosis as a common complication of β-thalassemia intermedia syndrome should be considered even in HbH which shows its prevalence is less than β-thalassemia intermedia.
Literature
1.
Steinberg MH, Forget BG, Higgs D R, Nagel RL (2001) Molecular mechanisms of a-thalassemia. Disorders of hemoglobin: Genetics, pathophysiology, and clinical management. Cambridge University Press 405–430
2.
Laosombat V, Viprakasit V, Chotsampancharoen T, Wongchanchailert M, Khodchawan S, Chinchang W, Sattayasevana B (2009) Clinical features and molecular analysis in Thai patients with HbH disease. Ann Hematol 88(12):1185–1192CrossRefPubMed
3.
Fucharoen S, Winichagoon P (2012) New updating into hemoglobinopathies. Int J Lab Hematol 34(6):559–565CrossRefPubMed
4.
Fucharoen S, Viprakasit V (2009) Hb H disease: clinical course and disease modifiers. ASH Education Program Book 2009(1):26–34
5.
Chui DH, Fucharoen S, Chan V (2003) Hemoglobin H disease: not necessarily a benign disorder. Blood 101(3):791–800CrossRefPubMed
6.
Higgs DR, Wood WG, Barton C, Weatherall DJ (1983) Clinical features and molecular analysis of acquired hemoglobin H disease. Am J Med 75(2):181–191CrossRefPubMed
7.
Organization WH (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization, Geneva
8.
Larijani B, Resch H, Bonjour J, Meybodi HA, Tehrani MM (2007) Osteoporosis in Iran, overview and management. Supplementary issue on osteoporosis, Iranian Journal of Public Health:1–13
9.
De Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, Sobti P, Skordis N, Karimi M, Raiola G (2013) Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 11(2):167–180PubMed
10.
Stewart T, Ralston S (2000) Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 166(2):235–245CrossRefPubMed
11.
Di Stefano M, Chiabotto P, Roggia C, Garofalo F, Lala R, Piga A, Isaia GC (2004) Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 22(1):53–57CrossRefPubMed
12.
13.
Dines D, Canale V, Arnold W (1976) Fractures in thalassemia. J Bone Joint Surg 58(5):662–666PubMed
14.
Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S (2007) Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr 44(1):29PubMed
15.
Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW (2000) Bone mineral metabolism in adults with β‐thalassaemia major and intermedia. Br J Haematol 111(3):902–907
16.
Dehbozorgian J, Moghadam M, Daryanoush S, Haghpanah S, Imani fard J, Aramesh A, Shahsavani A, Karimi M (2015) Distribution of alpha-thalassemia mutations in Iranian population. Hematology 20(6):359–62
17.
Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, Fuleihan GE-H, Kecskemethy HH, Jaworski M, Gordon CM (2014) Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom 17(2):225–242CrossRefPubMed
18.
Vogiatzi M, Macklin E, Fung E, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina P (2006) Prevalence of fractures among the Thalassemia syndromes in North America. Bone 38(4):571–575CrossRefPubMed
19.
Jensen C, Tuck S, Agnew J, Koneru S, Morris R, Yardumian A, Prescott E, Hoffbrand A, Wonke B (1998) High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11 Suppl 3:975–7
20.
Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia. Br J Haematol 123(4):730–737CrossRefPubMed
21.
Chan Y-L, Pang L-M, Chik K-W, Cheng JC, Li C-K (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32(7):492–497CrossRefPubMed
22.
Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I (1999) Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int 64(6):481–484CrossRefPubMed
23.
Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ (2005) Low bone mineral density in adolescents with β‐thalassemia. Ann N Y Acad Sci 1054(1):462–466CrossRefPubMed
24.
Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543–557CrossRefPubMed
25.
Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13(8):644–649CrossRefPubMed
26.
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned M-S, El-Chafic A-H, Fasulo MR, Cappellini MD (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115 (10):1886-1892
Metadata
Title
Evaluation of bone mineral density in patients with hemoglobin H disease
Authors
Tahereh Zarei
Sezaneh Haghpanah
Shirin Parand
Hossein Moravej
Mohammad Hossein Dabbaghmanesh
Gholamhossein Ranjbar Omrani
Mehran Karimi
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2708-9

Other articles of this Issue 8/2016

Annals of Hematology 8/2016 Go to the issue

Letter to the Editor

Multiple cytokine-producing primary cutaneous anaplastic large cell lymphoma

Letter to the Editor

Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual

Original Article

BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features

Original Article

The prevalence of chromosomal aberrations associated with myelodysplastic syndromes in China

Original Article

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

Review Article

Non-invasive prenatal diagnosis of β-thalassemia by detection of the cell-free fetal DNA in maternal circulation: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits